G Parker1. 1. School of Psychiatry, University of New South Wales and Black Dog Institute, Sydney, NSW, Australia. g.parker@unsw.edu.au
Abstract
OBJECTIVE: To argue that melancholia is a categorically distinct depressive condition, able to be differentiated from other depressive conditions by a neuropathological marker [observable psychomotor disturbance (PMD)] and having a differential response to various antidepressant treatments. METHOD: The above statements are addressed by review of a wide body of research, which identified observable PMD as the cardinal marker of melancholia and developed the CORE measure as a strategy for assessing PMD and its severity. Properties of the CORE measure, including reliability, validity and treatment prediction, are overviewed. RESULTS: A case is made for defining melancholia and a strategy for establishing its probability. CONCLUSION: Melancholia is positioned as a categorical entity capable of being circumscribed by its cardinal feature of PMD.
OBJECTIVE: To argue that melancholia is a categorically distinct depressive condition, able to be differentiated from other depressive conditions by a neuropathological marker [observable psychomotor disturbance (PMD)] and having a differential response to various antidepressant treatments. METHOD: The above statements are addressed by review of a wide body of research, which identified observable PMD as the cardinal marker of melancholia and developed the CORE measure as a strategy for assessing PMD and its severity. Properties of the CORE measure, including reliability, validity and treatment prediction, are overviewed. RESULTS: A case is made for defining melancholia and a strategy for establishing its probability. CONCLUSION:Melancholia is positioned as a categorical entity capable of being circumscribed by its cardinal feature of PMD.
Authors: S Calugi; G B Cassano; A Litta; P Rucci; A Benvenuti; M Miniati; L Lattanzi; V Mantua; V Lombardi; A Fagiolini; E Frank Journal: J Affect Disord Date: 2010-09-15 Impact factor: 4.839
Authors: Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11 Impact factor: 5.270
Authors: R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin Journal: Psychol Med Date: 2011-09-20 Impact factor: 7.723
Authors: Saray Monzón; Margalida Gili; Margalida Vives; Maria Jesus Serrano; Natalia Bauza; Rosa Molina; Mauro García-Toro; Joan Salvà; Joan Llobera; Miquel Roca Journal: BMC Psychiatry Date: 2010-06-17 Impact factor: 3.630